ArticlePlastic and reconstructive surgery. Global open2026
Bulging of the Masseter Muscle Following Botulinum Neurotoxin Type A Injection.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin toxin type A is widely used in the management of facial paralysis to reduce synkinesis and improve facial symmetry. Although the masseter muscle is not innervated by the facial nerve, aberrant reinnervation may lead to abnormal activity requiring treatment. We report the case of a 48-year-old woman with long-standing, partially regenerated right-sided facial palsy who developed paradoxical masseter muscle bulging following botulinum neurotoxin toxin type A injection. After a single injection targeting masseter hypertonicity, the patient exhibited a visible bulge during clenching. Ultrasound imaging revealed superficial muscle bulging associated with intramuscular septations. Uneven toxin diffusion caused by internal tendinous barriers within the masseter muscle was identified as the most likely mechanism. This case highlights the importance of understanding masseter anatomy and applying precise injection techniques to minimize adverse effects and optimize therapeutic outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.